Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Identification of chelerythrine as an inhibitor of BclXL function.

Chan SL, Lee MC, Tan KO, Yang LK, Lee AS, Flotow H, Fu NY, Butler MS, Soejarto DD, Buss AD, Yu VC.

J Biol Chem. 2003 Jun 6;278(23):20453-6. Epub 2003 Apr 17.

2.

A role for mitochondrial Bak in apoptotic response to anticancer drugs.

Wang GQ, Gastman BR, Wieckowski E, Goldstein LA, Gambotto A, Kim TH, Fang B, Rabinovitz A, Yin XM, Rabinowich H.

J Biol Chem. 2001 Sep 7;276(36):34307-17. Epub 2001 Jul 10.

3.

Chelerythrine induces apoptosis through a Bax/Bak-independent mitochondrial mechanism.

Wan KF, Chan SL, Sukumaran SK, Lee MC, Yu VC.

J Biol Chem. 2008 Mar 28;283(13):8423-33. doi: 10.1074/jbc.M707687200. Epub 2008 Jan 29.

4.

Interferon-alpha-induced apoptosis in U266 cells is associated with activation of the proapoptotic Bcl-2 family members Bak and Bax.

Panaretakis T, Pokrovskaja K, Shoshan MC, Grandér D.

Oncogene. 2003 Jul 17;22(29):4543-56.

PMID:
12881711
6.

Induction of apoptosis in prostate carcinoma cells by BH3 peptides which inhibit Bak/Bcl-2 interactions.

Finnegan NM, Curtin JF, Prevost G, Morgan B, Cotter TG.

Br J Cancer. 2001 Jul 6;85(1):115-21.

7.

The mitochondrial effects of small organic ligands of BCL-2: sensitization of BCL-2-overexpressing cells to apoptosis by a pyrimidine-2,4,6-trione derivative.

Milanesi E, Costantini P, Gambalunga A, Colonna R, Petronilli V, Cabrelle A, Semenzato G, Cesura AM, Pinard E, Bernardi P.

J Biol Chem. 2006 Apr 14;281(15):10066-72. Epub 2006 Feb 14.

8.

Chelerythrine and sanguinarine dock at distinct sites on BclXL that are not the classic BH3 binding cleft.

Zhang YH, Bhunia A, Wan KF, Lee MC, Chan SL, Yu VC, Mok YK.

J Mol Biol. 2006 Dec 1;364(3):536-49. Epub 2006 Sep 14.

PMID:
17011577
10.

Characterization of the anti-apoptotic mechanism of Bcl-B.

Zhai D, Ke N, Zhang H, Ladror U, Joseph M, Eichinger A, Godzik A, Ng SC, Reed JC.

Biochem J. 2003 Nov 15;376(Pt 1):229-36.

11.

Mitochondrial release of AIF and EndoG requires caspase activation downstream of Bax/Bak-mediated permeabilization.

Arnoult D, Gaume B, Karbowski M, Sharpe JC, Cecconi F, Youle RJ.

EMBO J. 2003 Sep 1;22(17):4385-99.

12.

The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak.

Pérez-Galán P, Roué G, Villamor N, Campo E, Colomer D.

Blood. 2007 May 15;109(10):4441-9. Epub 2007 Jan 16.

13.

VDAC2 inhibits BAK activation and mitochondrial apoptosis.

Cheng EH, Sheiko TV, Fisher JK, Craigen WJ, Korsmeyer SJ.

Science. 2003 Jul 25;301(5632):513-7.

14.

Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL.

Degterev A, Lugovskoy A, Cardone M, Mulley B, Wagner G, Mitchison T, Yuan J.

Nat Cell Biol. 2001 Feb;3(2):173-82.

PMID:
11175750
15.

Mechanisms of cytochrome c release by proapoptotic BCL-2 family members.

Scorrano L, Korsmeyer SJ.

Biochem Biophys Res Commun. 2003 May 9;304(3):437-44. Review.

PMID:
12729577
16.

Hypoxia selection of death-resistant cells. A role for Bcl-X(L).

Dong Z, Wang J.

J Biol Chem. 2004 Mar 5;279(10):9215-21. Epub 2003 Dec 15.

17.

The chemopreventive agent N-(4-hydroxyphenyl)retinamide induces apoptosis through a mitochondrial pathway regulated by proteins from the Bcl-2 family.

Boya P, Morales MC, Gonzalez-Polo RA, Andreau K, Gourdier I, Perfettini JL, Larochette N, Deniaud A, Baran-Marszak F, Fagard R, Feuillard J, Asumendi A, Raphael M, Pau B, Brenner C, Kroemer G.

Oncogene. 2003 Sep 18;22(40):6220-30.

PMID:
13679861
18.
20.

The multidomain proapoptotic molecules Bax and Bak are directly activated by heat.

Pagliari LJ, Kuwana T, Bonzon C, Newmeyer DD, Tu S, Beere HM, Green DR.

Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):17975-80. Epub 2005 Dec 5.

Supplemental Content

Support Center